LUNG vs. NVDA

Last updated Jun 6, 2026

LUNG (Pulmonx Corporation) and NVDA (NVIDIA Corporation) are both stocks. LUNG operates in Medical Devices (Healthcare), while NVDA operates in Semiconductors (Technology). Over the past 5 years, LUNG returned -48.59%/yr vs 63.58%/yr for NVDA. At a 0.25 correlation, their price movements are largely independent.

Performance

LUNG vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pulmonx Corporation (LUNG) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LUNG achieves a -30.77% return, which is significantly lower than NVDA's 10.11% return.

LUNG

• 1D: -5.56%
• 1M: 18.60%
• YTD: -30.77%
• 6M: -23.88%
• 1Y: -48.48%
• 3Y*: -50.68%
• 5Y*: -48.59%
• 10Y*: —

NVDA

• 1D: -6.20%
• 1M: -1.20%
• YTD: 10.11%
• 6M: 12.58%
• 1Y: 46.72%
• 3Y*: 74.54%
• 5Y*: 63.58%
• 10Y*: 68.14%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LUNG vs. NVDA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
LUNG Pulmonx Corporation	-30.77%	-67.45%	-46.75%	51.25%	-73.71%	-53.54%	75.58%
NVDA NVIDIA Corporation	10.11%	38.92%	171.25%	239.02%	-50.26%	125.48%	-4.08%

Correlation

The correlation between LUNG and NVDA is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.18
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.25
Correlation (All Time) Calculated using the full available price history since Oct 2, 2020	0.25

The correlation between LUNG and NVDA shifts across timeframes, from 0.14 (3 years) to 0.25 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap LUNG : $64.10M NVDA : $5.00T
EPS LUNG : -$1.29 NVDA : $6.53
PS Ratio LUNG : 0.71 NVDA : 19.79
PB Ratio LUNG : 1.40 NVDA : 25.59
Total Revenue (TTM) LUNG : $88.55M NVDA : $253.49B
Gross Profit (TTM) LUNG : $66.84M NVDA : $187.95B
EBITDA (TTM) LUNG : -$49.54M NVDA : $192.76B

Return for Risk

LUNG vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LUNG

LUNG Risk / Return Rank: 22
LUNG Sharpe Ratio Rank: 20
LUNG Sortino Ratio Rank: 25
LUNG Omega Ratio Rank: 25
LUNG Calmar Ratio Rank: 15
LUNG Martin Ratio Rank: 23

NVDA

NVDA Risk / Return Rank: 76
NVDA Sharpe Ratio Rank: 79
NVDA Sortino Ratio Rank: 73
NVDA Omega Ratio Rank: 70
NVDA Calmar Ratio Rank: 77
NVDA Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LUNG vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pulmonx Corporation (LUNG) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LUNG	NVDA	Difference
Sharpe ratio: Return per unit of total volatility	-0.50	1.35	-1.85
Sortino ratio: Return per unit of downside risk	-0.24	1.92	-2.17
Omega ratio: Gain probability vs. loss probability	0.97	1.23	-0.26
Calmar ratio: Return relative to maximum drawdown	-0.70	2.32	-3.03
Martin ratio: Return relative to average drawdown	-0.92	5.67	-6.59
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LUNG vs. NVDA - Sharpe Ratio Comparison

The current LUNG Sharpe Ratio is -0.50, which is lower than the NVDA Sharpe Ratio of 1.35. The chart below compares the historical Sharpe Ratios of LUNG and NVDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	LUNG	NVDA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.50	1.35	-1.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.61	1.23	-1.85
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.37	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.56	0.62	-1.18

Drawdowns

LUNG vs. NVDA - Drawdown Comparison

The maximum LUNG drawdown since its inception was -98.30%, which is greater than NVDA's maximum drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for LUNG and NVDA.

Drawdown Indicators

	LUNG	NVDA	Difference
Max Drawdown Largest peak-to-trough decline	-98.30%	-89.72%	-8.58%
Max Drawdown (1Y) Largest decline over 1 year	-69.05%	-20.21%	-48.84%
Max Drawdown (3Y) Largest decline over 3 years	-92.01%	-36.88%	-55.13%
Max Drawdown (5Y) Largest decline over 5 years	-97.43%	-66.34%	-31.09%
Max Drawdown (10Y) Largest decline over 10 years	—	-66.34%	—
Current Drawdown Current decline from peak	-97.78%	-12.90%	-84.88%
Average Drawdown Average peak-to-trough decline	-73.78%	-36.20%	-37.58%
Ulcer Index Depth and duration of drawdowns from previous peaks	52.48%	8.27%	+44.21%

Volatility

LUNG vs. NVDA - Volatility Comparison

Pulmonx Corporation (LUNG) has a higher volatility of 21.81% compared to NVIDIA Corporation (NVDA) at 13.15%. This indicates that LUNG's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LUNG	NVDA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.81%	13.15%	+8.66%
Volatility (6M) Calculated over the trailing 6-month period	55.81%	26.39%	+29.42%
Volatility (1Y) Calculated over the trailing 1-year period	97.45%	34.76%	+62.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	79.48%	51.73%	+27.75%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.92%	49.84%	+28.08%

Dividends

LUNG vs. NVDA - Dividend Comparison

LUNG has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.14%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LUNG Pulmonx Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVDA NVIDIA Corporation	0.14%	0.02%	0.03%	0.03%	0.11%	0.05%	0.12%	0.27%	0.46%	0.29%	0.45%	1.20%

Financials

LUNG vs. NVDA - Profitability Comparison

The chart below illustrates the profitability comparison between Pulmonx Corporation and NVIDIA Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LUNG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pulmonx Corporation reported a gross profit of 16.04M and revenue of 20.59M. Therefore, the gross margin over that period was 77.9%.

NVDA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported a gross profit of 61.16B and revenue of 81.62B. Therefore, the gross margin over that period was 74.9%.

LUNG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pulmonx Corporation reported an operating income of -12.96M and revenue of 20.59M, resulting in an operating margin of -62.9%.

NVDA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported an operating income of 53.54B and revenue of 81.62B, resulting in an operating margin of 65.6%.

LUNG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pulmonx Corporation reported a net income of -13.65M and revenue of 20.59M, resulting in a net margin of -66.3%.

NVDA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NVIDIA Corporation reported a net income of 58.32B and revenue of 81.62B, resulting in a net margin of 71.5%.

Frequently Asked Questions

Can I hold both LUNG and NVDA in my portfolio?

LUNG and NVDA have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LUNG or NVDA?

LUNG has higher volatility (21.81%) compared to NVDA (13.15%). In terms of maximum drawdown, LUNG dropped -98.30% vs NVDA's -89.72%.

Which has better risk-adjusted returns?

NVDA currently has the higher Sharpe Ratio (1.35 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.